Informal four-component blend label
KLOW is a community label commonly used for a mixture described as GHK-Cu, BPC-157, TB-500, and KPV. No study was located testing all four together.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
The available record consists of four separate ingredient records and documented searches that found no exact-combination study.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
No direct evidence establishes benefit, synergy, compatibility, stability, safety, or pharmacokinetics for the four-component mixture.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Ingredient studies use different routes, formulations, populations, and endpoints. FDA located no human TB-500 or KPV administration, and no component record establishes a SubQ KLOW protocol or safety profile. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
What the evidence says
None for KLOW as a blend. The strongest component-level human evidence comes from specific topical GHK-Cu studies; it cannot establish injectable KLOW.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
The blend's identity and ratio, chemical and physical compatibility, stability after mixing, sterility, pharmacokinetics, interactions, immunogenicity, dose-response, safety, and clinical effects.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
A July 2026 PubMed audit found no study administering GHK-Cu, BPC-157, TB-500, and KPV together.
A July 2026 ClinicalTrials.gov audit found no registered study of the exact four-component combination.
No results are posted. The registration cannot establish benefit for BPC-157 or for any blend.
Parent TB-500 did not improve fibroblast scratch-wound closure at the tested concentration; one shorter metabolite showed activity.
Fourteen of 16 people reported relief overall. Three of the four people in the two-material subgroup reported relief.
Administration and handling
No human trial or approved label establishes a KLOW route, dose, schedule, ratio, or reconstitution process. Published component studies use different formulations and routes, while FDA located no human TB-500 or KPV administration. Those records cannot be combined into guidance.
No published compatibility or stability study was located for GHK-Cu, BPC-157, TB-500, and KPV mixed together. Individual ingredient storage notes cannot establish blend stability, sterility, precipitation risk, aggregation risk, container compatibility, or beyond-use time.
Primary-source ledger
2026-07-25
2026-07-25
2026-07-24
2026-07-23
2026-07-21
2026-05-14
2026-05-12
2026-02-27 · NCT07437547
2024-03-15 · PMID 38382158 · DOI 10.1016/j.jchromb.2024.124033
2021-07-01 · PMID 34324435
2008-01-01 · PMID 18061177 · DOI 10.1053/j.gastro.2007.10.026
1994-10-01 · PMID 17147644 · DOI 10.1046/j.1524-475X.1994.20406.x